Going Concern Warning Issued Amidst Pending Merger and Significant Dilutive Financing

summarizeSummary

Coeptis Therapeutics faces a going concern warning and is engaged in dilutive financing efforts while pursuing a transformational merger and restructuring executive equity compensation.

check_boxKey Events

• Substantial Doubt About Going Concern

  The company's independent auditor has issued an explanatory paragraph indicating 'substantial doubt about our ability to continue as a going concern' due to a history of significant losses and negative operating cash flows, highlighting immediate financial viability risks.

• Transformational Merger with Z Squared Pending

  Coeptis is proceeding with a merger with Z Squared, Inc., expected to close in Q2 2026, which will involve a spin-out of its biotechnology operations. Nasdaq has already approved the listing of the post-merger company's common stock.

• Significant Dilutive Capital Raises Underway

  The company has a Standby Equity Purchase Agreement (SEPA) with Yorkville for up to $20 million in common stock sales, representing a potential dilution of approximately 22% of the current market capitalization. Convertible notes from Yorkville were also converted into common stock in 2025.

• Executive and Director Equity Compensation Restructured

  A subsequent event in February 2026 involved an option repricing and exchange program where officers and directors surrendered 112,500 options for 112,500 restricted shares, and exercised 198,375 options for restricted common stock, resulting in significant equity issuance.

auto_awesomeAnalysis

This prospectus supplement incorporates the company's Annual Report on Form 10-K, which reveals a 'substantial doubt about our ability to continue as a going concern' due to significant losses and negative operating cash flows. This critical financial distress is disclosed as the company actively seeks to raise capital through dilutive means, including a Standby Equity Purchase Agreement (SEPA) for up to $20 million. The filing also details a pending transformational merger with Z Squared, Inc., expected to close in Q2 2026, which includes a spin-out of Coeptis's biotechnology operations. While the merger offers a potential path forward, the immediate financial viability remains a significant concern for investors. Additionally, a recent option repricing and exchange program for executives and directors resulted in the issuance of a substantial number of restricted shares, further impacting the equity structure.